HIMS records subscriber surge and revenue growth in second-quarter 2025, but rising costs strain gross margins.

Insider moves in IonQ, Hims and Hers, Eli Lilly, and TransMedics reveal bold buys, record sales, and signals worth watching.

While Wall Street analysts remain cautious on Hims & Hers Health ($HIMS), TipRanks’ A.I. Stock Analysis tool shows strong ...

Insider Transactions Analysis Can Help with Conviction Insider transactions, particularly insider buys, are a valuable tool for investors to monitor because they can provide insight into how the ...

Doctors report insurance cuts are forcing many U.S. patients on Wegovy and Zepbound to pay high out-of-pocket costs.

Detailed price information for Gsi Technology Inc (GSIT-Q) from The Globe and Mail including charting and trades.